Clinical Performance of CEAT

Analysis of remote treatment results in prostate cancers

Of the 250 patients who received a definitive diagnosis of prostate cancer and were treated at our clinic from 2001 through 2011, 84 were irradiated with microwaves, and of those 71 were irradiated three times or more. 41of these 71 patients were classified as stage D, comprising mostly of serious cases with complication of bone metastases.  Nevertheless, the five-year survival rate of these 41 patients was 50.0%. This is considered a significantly better result than the five-year survival rate, at 20.0-30.0%, of the stage D patients with distant metastases receiving conventional medicine treatment (National Cancer Center, Japan).
     More than 30.0% of the stage D patients were aged 65 to 76 years old. 60.0% of the total patients received hormone therapy; 4.0% underwent surgery; 7.0% received radiotherapy; and 1.0% chemotherapy. 48.0% had metastases to the bone, 5.0% to the lymph nodes, 3.0% to the bladder, 2.0% to the lungs, and 1.0% to the retroperitoneum. In the treatment of prostate cancer, we do not recommend any invasive therapies including surgery and anti-cancer drugs or any other therapeutic methods that may produce side effects or aftereffects. The purpose of our treatment is to annihilate the cancer activity; hence our treatment policy is consistent regardless of the patient’s age or degree of progress. Microwaves are irradiated frequently and locally on bone metastatic regions until the cancer activity, including that which is spreading, is annihilated. Conventional therapies are used simultaneously for associated pain in bone regions. As a supplementary therapy, we advise most of our patients to use a far infrared thermal heater on localized areas at home. For supplements, 49.0% are advised to take propolis, 45.0% vitamin C, and 23.0% shark cartilage extract.